<?xml version="1.0" encoding="UTF-8"?>
<p id="Par57">Many mAbs products achieved annual sales of over US$3 billion in 2018 (Fig. 
 <xref rid="Fig1" ref-type="fig">1</xref>), while six (adalimumab, nivolumab, pembrolizumab, trastuzumab, bevacizumab, rituximab) had sales of more than $6 billion (TableÂ 
 <xref rid="Tab2" ref-type="table">2</xref>). Adalimumab (Humira) had the highest sales figure ever recorded for a biopharmaceutical product, nearly $19.9 billion. The top ten selling mAb products in 2018 are listed in Table 
 <xref rid="Tab2" ref-type="table">2</xref>. Top-selling mAb drugs were ranked based on sales or revenue reported by biological or pharmacological companies in press announcements, conference calls, annual reports or investor materials throughout 2018. For each drug, the name, sponsors, disease indications, and 2018 sales are shown. 
</p>
